Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market

2026-03-10 23:38:48

Abstract generation in progress

RBC Capital Markets initiated coverage on Rhythm Pharmaceuticals (NASDAQ: RYTM) with an Outperform rating and a $145 price target, highlighting the company’s leading position in the rare genetic obesity market. The analyst anticipates that Rhythm’s drug Imcivree, following successful Phase 3 trials for hypothalamic obesity, could generate over $2 billion in revenue by 2030 by expanding its addressable market significantly. The company is also developing next-generation assets and researching setmelanotide for Prader-Willi Syndrome, further positioning it for future growth.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes